Dômes Pharma has finalized its acquisition of SentrX Animal Care, a Salt Lake City company that develops and manufactures veterinary ophthalmology products based on its exclusive BioHAnce technology. BioHAnce is a patented crosslinked hyaluronic acid technology that enhances and accelerates natural healing, hydration and lubrication processes, while reducing the number of applications. The company, which has its own manufacturing plant, markets three products that have rapidly gained market share in the United States and Europe, notably in the U.K.
“Less than a year after the opening of a{mprestriction ids="1,3"} subsidiary in Boston, this acquisition marks an important step in Dômes Pharma’s ambitions in North America and confirms its positioning in veterinary ophthalmology,” the Pont-du-Chateau, France-based company said in a release. Since 2015, Dômes Pharma has undertaken international expansion with the opening of subsidiaries in England, Germany, Spain and most recently the U.S., alongside a network of distributors in Europe.
“We are delighted to have finalized the acquisition of SentrX Animal Care in such a short space of time,” said Anne Moulin, president of Dômes Pharma U.S. “The geographic, industrial and therapeutic synergies between our two companies are so obvious that we were made for each other. For both SentrX and us, this acquisition comes at the right time, and will enable us to continue to assert our expertise in ophthalmology in Europe, and to establish ourselves in North America in one of the company’s areas of excellence. It’s a fantastic opportunity for us to expand more rapidly in the U.S., while awaiting the forthcoming FDA registration of our products.”
“The Dômes Pharma organization has an impressive long-standing track record of excellence in bringing products to market that improve the lives of pets and those who care for them,” said Brian Segebrecht, the former president and CEO of SentrX. “However, throughout this sale process I have been most impressed by a shared set of values and aspirations between the two companies, particularly in the field of veterinary ophthalmology. As a result of this transaction more pet owners and veterinarians in more markets will have access to an improved offering of innovative ophthalmology solutions, ultimately improving the lives of more animals around the world, which is exciting.”
Financial details of the acquisition were not disclosed.{/mprestriction}
